Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of GW815SF HFA MDI with salmeterol DPI plus fluticasone DPI and assessment of long-term safety in pediatric asthma
2015-004882-10Phase 3
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of salmeterol + fluticasone propionate in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in morning peak expiratory flow (PEF).
02
Drugs
salmeterol + fluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-004882-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004882-10.